Please assess the completion status of the following clinical trial:

Trial Title: Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* hereditary hemorrhagic telangiectasia with nosebleeds and desire to be treated.~Exclusion Criteria:~* pregnant,~* minor,~* had an increased risk of thrombotic events (history or signs of cerebrovascular events, cardiac arrhythmias, biochemically increased coagulation parameters),~* renal insufficiency,~* a history of massive hematuria or defects of color vision.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group I (Type: EXPERIMENTAL): First verum (3 times 1 g Tranexamic acid daily) for three months, than placebo for 3 months.
- Group II (Type: EXPERIMENTAL): First placebo for 3 months, than verum for 3 months (3 times 1 g Tranexamic acid daily).

Based on this trial design, predict the completion outcome and termination type (if applicable).